D. E. Shaw & Co. Inc. raised its stake in Agenus Inc (NASDAQ:AGEN) by 20.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,477,585 shares of the biotechnology company’s stock after acquiring an additional 412,679 shares during the period. D. E. Shaw & Co. Inc. owned approximately 2.06% of Agenus worth $5,897,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Two Sigma Securities LLC purchased a new stake in shares of Agenus in the fourth quarter worth $31,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Agenus by 272.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,105 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 23,493 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Agenus during the third quarter valued at $105,000. Rhumbline Advisers lifted its holdings in shares of Agenus by 50.3% during the fourth quarter. Rhumbline Advisers now owns 112,015 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 37,463 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Agenus by 111.8% during the fourth quarter. Bank of America Corp DE now owns 150,367 shares of the biotechnology company’s stock valued at $358,000 after purchasing an additional 79,364 shares in the last quarter. 28.39% of the stock is currently owned by hedge funds and other institutional investors.
AGEN has been the topic of a number of research analyst reports. ValuEngine raised Agenus from a “hold” rating to a “buy” rating in a report on Thursday, January 17th. BidaskClub raised Agenus from a “hold” rating to a “buy” rating in a report on Thursday, January 10th. Finally, Zacks Investment Research downgraded Agenus from a “hold” rating to a “sell” rating in a report on Tuesday, January 8th.
Shares of NASDAQ:AGEN opened at $2.86 on Friday. Agenus Inc has a 1 year low of $1.54 and a 1 year high of $4.80.
Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.12). The firm had revenue of $5.36 million during the quarter, compared to analysts’ expectations of $6.67 million. Research analysts predict that Agenus Inc will post -1.27 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Macon Daily and is the property of of Macon Daily. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://macondaily.com/2019/03/29/d-e-shaw-co-inc-buys-412679-shares-of-agenus-inc-agen.html.
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Further Reading: Trading Stocks – What are percentage gainers?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.